nodes	percent_of_prediction	percent_of_DWPC	metapath
Ketamine—ABCB1—lung cancer	0.166	1	CbGaD
Ketamine—PTGS1—Etoposide—lung cancer	0.0276	0.0508	CbGbCtD
Ketamine—ABCB1—Topotecan—lung cancer	0.0276	0.0507	CbGbCtD
Ketamine—CYP2B6—Irinotecan—lung cancer	0.0263	0.0483	CbGbCtD
Ketamine—CYP2C9—Gefitinib—lung cancer	0.026	0.0478	CbGbCtD
Ketamine—ABCB1—Gefitinib—lung cancer	0.0252	0.0464	CbGbCtD
Ketamine—CYP2C9—Teniposide—lung cancer	0.0252	0.0464	CbGbCtD
Ketamine—CYP2C8—Erlotinib—lung cancer	0.022	0.0405	CbGbCtD
Ketamine—CYP2B6—Cisplatin—lung cancer	0.0214	0.0394	CbGbCtD
Ketamine—CYP2C8—Paclitaxel—lung cancer	0.0202	0.0371	CbGbCtD
Ketamine—ABCB1—Vinorelbine—lung cancer	0.0194	0.0357	CbGbCtD
Ketamine—CYP3A4—Topotecan—lung cancer	0.0165	0.0304	CbGbCtD
Ketamine—CYP2C8—Etoposide—lung cancer	0.0159	0.0293	CbGbCtD
Ketamine—ABCB1—Crizotinib—lung cancer	0.0155	0.0284	CbGbCtD
Ketamine—CYP3A4—Gefitinib—lung cancer	0.0151	0.0278	CbGbCtD
Ketamine—ABCB1—Gemcitabine—lung cancer	0.0151	0.0278	CbGbCtD
Ketamine—ABCB1—Erlotinib—lung cancer	0.0149	0.0274	CbGbCtD
Ketamine—CYP3A4—Teniposide—lung cancer	0.0146	0.027	CbGbCtD
Ketamine—CYP2B6—Doxorubicin—lung cancer	0.0143	0.0264	CbGbCtD
Ketamine—CYP2C9—Paclitaxel—lung cancer	0.0141	0.0259	CbGbCtD
Ketamine—ABCB1—Paclitaxel—lung cancer	0.0136	0.0251	CbGbCtD
Ketamine—ABCB1—Irinotecan—lung cancer	0.0135	0.0248	CbGbCtD
Ketamine—ABCB1—Vinblastine—lung cancer	0.012	0.022	CbGbCtD
Ketamine—CYP3A4—Vinorelbine—lung cancer	0.0116	0.0214	CbGbCtD
Ketamine—CYP2C9—Cisplatin—lung cancer	0.0113	0.0208	CbGbCtD
Ketamine—ABCB1—Cisplatin—lung cancer	0.011	0.0202	CbGbCtD
Ketamine—ABCB1—Etoposide—lung cancer	0.0108	0.0198	CbGbCtD
Ketamine—ABCB1—Docetaxel—lung cancer	0.00986	0.0182	CbGbCtD
Ketamine—CYP3A4—Crizotinib—lung cancer	0.00926	0.017	CbGbCtD
Ketamine—CYP3A4—Erlotinib—lung cancer	0.00893	0.0164	CbGbCtD
Ketamine—Clonus—Cisplatin—lung cancer	0.00889	0.0833	CcSEcCtD
Ketamine—CYP3A4—Paclitaxel—lung cancer	0.00818	0.015	CbGbCtD
Ketamine—CYP3A4—Irinotecan—lung cancer	0.00806	0.0148	CbGbCtD
Ketamine—ABCB1—Doxorubicin—lung cancer	0.00735	0.0135	CbGbCtD
Ketamine—CYP3A4—Vinblastine—lung cancer	0.00717	0.0132	CbGbCtD
Ketamine—ABCB1—Methotrexate—lung cancer	0.00712	0.0131	CbGbCtD
Ketamine—CYP3A4—Etoposide—lung cancer	0.00646	0.0119	CbGbCtD
Ketamine—CYP3A4—Docetaxel—lung cancer	0.00591	0.0109	CbGbCtD
Ketamine—CYP3A4—Doxorubicin—lung cancer	0.00441	0.00811	CbGbCtD
Ketamine—Cystitis noninfective—Gefitinib—lung cancer	0.00258	0.0242	CcSEcCtD
Ketamine—Cystitis—Gefitinib—lung cancer	0.00256	0.024	CcSEcCtD
Ketamine—Obstructive airways disorder—Methotrexate—lung cancer	0.00248	0.0232	CcSEcCtD
Ketamine—Bladder pain—Gefitinib—lung cancer	0.00239	0.0224	CcSEcCtD
Ketamine—Nystagmus—Vinblastine—lung cancer	0.0023	0.0216	CcSEcCtD
Ketamine—Diplopia—Crizotinib—lung cancer	0.00212	0.0198	CcSEcCtD
Ketamine—Bradycardia—Crizotinib—lung cancer	0.00149	0.014	CcSEcCtD
Ketamine—Arrhythmia—Crizotinib—lung cancer	0.00131	0.0123	CcSEcCtD
Ketamine—Laryngospasm—Etoposide—lung cancer	0.00126	0.0118	CcSEcCtD
Ketamine—Vision blurred—Crizotinib—lung cancer	0.0012	0.0113	CcSEcCtD
Ketamine—Arrhythmia—Pemetrexed—lung cancer	0.00119	0.0112	CcSEcCtD
Ketamine—Arrhythmia—Gefitinib—lung cancer	0.00119	0.0111	CcSEcCtD
Ketamine—Erythema—Pemetrexed—lung cancer	0.00116	0.0109	CcSEcCtD
Ketamine—Apnoea—Etoposide—lung cancer	0.00111	0.0104	CcSEcCtD
Ketamine—Salivary hypersecretion—Irinotecan—lung cancer	0.0011	0.0103	CcSEcCtD
Ketamine—Shock—Crizotinib—lung cancer	0.00102	0.00959	CcSEcCtD
Ketamine—Arrhythmia—Teniposide—lung cancer	0.000968	0.00908	CcSEcCtD
Ketamine—Anaphylactic shock—Pemetrexed—lung cancer	0.00095	0.00891	CcSEcCtD
Ketamine—Shock—Pemetrexed—lung cancer	0.000935	0.00877	CcSEcCtD
Ketamine—Shock—Gefitinib—lung cancer	0.000929	0.00871	CcSEcCtD
Ketamine—Anorexia—Pemetrexed—lung cancer	0.000906	0.0085	CcSEcCtD
Ketamine—Decreased appetite—Crizotinib—lung cancer	0.000904	0.00848	CcSEcCtD
Ketamine—Anorexia—Gefitinib—lung cancer	0.0009	0.00844	CcSEcCtD
Ketamine—Hypotension—Gefitinib—lung cancer	0.000882	0.00827	CcSEcCtD
Ketamine—Decreased appetite—Pemetrexed—lung cancer	0.000826	0.00775	CcSEcCtD
Ketamine—Decreased appetite—Gefitinib—lung cancer	0.000821	0.0077	CcSEcCtD
Ketamine—Pain—Pemetrexed—lung cancer	0.000813	0.00762	CcSEcCtD
Ketamine—Pain—Gefitinib—lung cancer	0.000807	0.00757	CcSEcCtD
Ketamine—Anorexia—Teniposide—lung cancer	0.000734	0.00688	CcSEcCtD
Ketamine—Hypotension—Teniposide—lung cancer	0.000719	0.00675	CcSEcCtD
Ketamine—Arrhythmia—Erlotinib—lung cancer	0.00071	0.00666	CcSEcCtD
Ketamine—Erythema—Erlotinib—lung cancer	0.000692	0.00649	CcSEcCtD
Ketamine—Nystagmus—Doxorubicin—lung cancer	0.000681	0.00639	CcSEcCtD
Ketamine—Decreased appetite—Teniposide—lung cancer	0.000669	0.00628	CcSEcCtD
Ketamine—Apnoea—Methotrexate—lung cancer	0.000663	0.00622	CcSEcCtD
Ketamine—Vomiting—Crizotinib—lung cancer	0.000661	0.0062	CcSEcCtD
Ketamine—Rash—Crizotinib—lung cancer	0.000656	0.00615	CcSEcCtD
Ketamine—Dermatitis—Crizotinib—lung cancer	0.000655	0.00614	CcSEcCtD
Ketamine—Convulsion—Vinblastine—lung cancer	0.000623	0.00585	CcSEcCtD
Ketamine—Nausea—Crizotinib—lung cancer	0.000618	0.00579	CcSEcCtD
Ketamine—Arrhythmia—Vinorelbine—lung cancer	0.000614	0.00576	CcSEcCtD
Ketamine—Vomiting—Pemetrexed—lung cancer	0.000604	0.00567	CcSEcCtD
Ketamine—Vomiting—Gefitinib—lung cancer	0.0006	0.00563	CcSEcCtD
Ketamine—Rash—Pemetrexed—lung cancer	0.000599	0.00562	CcSEcCtD
Ketamine—Dermatitis—Pemetrexed—lung cancer	0.000599	0.00561	CcSEcCtD
Ketamine—Erythema—Vinorelbine—lung cancer	0.000598	0.00561	CcSEcCtD
Ketamine—Rash—Gefitinib—lung cancer	0.000595	0.00558	CcSEcCtD
Ketamine—Dermatitis—Gefitinib—lung cancer	0.000595	0.00558	CcSEcCtD
Ketamine—Bradycardia—Irinotecan—lung cancer	0.000577	0.00541	CcSEcCtD
Ketamine—Anaphylactic shock—Topotecan—lung cancer	0.00057	0.00535	CcSEcCtD
Ketamine—Nausea—Pemetrexed—lung cancer	0.000564	0.00529	CcSEcCtD
Ketamine—Nausea—Gefitinib—lung cancer	0.000561	0.00526	CcSEcCtD
Ketamine—Anorexia—Vinblastine—lung cancer	0.00056	0.00525	CcSEcCtD
Ketamine—Shock—Erlotinib—lung cancer	0.000555	0.00521	CcSEcCtD
Ketamine—Cystitis noninfective—Methotrexate—lung cancer	0.000549	0.00515	CcSEcCtD
Ketamine—Anorexia—Topotecan—lung cancer	0.000544	0.0051	CcSEcCtD
Ketamine—Cystitis—Methotrexate—lung cancer	0.000543	0.00509	CcSEcCtD
Ketamine—Anorexia—Erlotinib—lung cancer	0.000538	0.00505	CcSEcCtD
Ketamine—Bradycardia—Cisplatin—lung cancer	0.000524	0.00491	CcSEcCtD
Ketamine—Decreased appetite—Vinblastine—lung cancer	0.00051	0.00479	CcSEcCtD
Ketamine—Bladder pain—Methotrexate—lung cancer	0.000508	0.00477	CcSEcCtD
Ketamine—Arrhythmia—Irinotecan—lung cancer	0.000506	0.00475	CcSEcCtD
Ketamine—Pain—Vinblastine—lung cancer	0.000502	0.00471	CcSEcCtD
Ketamine—Decreased appetite—Topotecan—lung cancer	0.000496	0.00465	CcSEcCtD
Ketamine—Arrhythmia—Gemcitabine—lung cancer	0.000493	0.00462	CcSEcCtD
Ketamine—Decreased appetite—Erlotinib—lung cancer	0.000491	0.0046	CcSEcCtD
Ketamine—Vomiting—Teniposide—lung cancer	0.000489	0.00459	CcSEcCtD
Ketamine—Anaphylactic shock—Vinorelbine—lung cancer	0.000488	0.00458	CcSEcCtD
Ketamine—Pain—Topotecan—lung cancer	0.000488	0.00458	CcSEcCtD
Ketamine—Rash—Teniposide—lung cancer	0.000485	0.00455	CcSEcCtD
Ketamine—Dermatitis—Teniposide—lung cancer	0.000485	0.00455	CcSEcCtD
Ketamine—Pain—Erlotinib—lung cancer	0.000483	0.00453	CcSEcCtD
Ketamine—Erythema—Gemcitabine—lung cancer	0.00048	0.00451	CcSEcCtD
Ketamine—Cystitis noninfective—Doxorubicin—lung cancer	0.000475	0.00446	CcSEcCtD
Ketamine—Salivary hypersecretion—Doxorubicin—lung cancer	0.000473	0.00443	CcSEcCtD
Ketamine—Bradycardia—Paclitaxel—lung cancer	0.00047	0.00441	CcSEcCtD
Ketamine—Cystitis—Doxorubicin—lung cancer	0.00047	0.00441	CcSEcCtD
Ketamine—Anorexia—Vinorelbine—lung cancer	0.000465	0.00436	CcSEcCtD
Ketamine—Arrhythmia—Cisplatin—lung cancer	0.000459	0.00431	CcSEcCtD
Ketamine—Nausea—Teniposide—lung cancer	0.000457	0.00429	CcSEcCtD
Ketamine—Hypotension—Vinorelbine—lung cancer	0.000456	0.00428	CcSEcCtD
Ketamine—Erythema—Cisplatin—lung cancer	0.000448	0.0042	CcSEcCtD
Ketamine—Bladder pain—Doxorubicin—lung cancer	0.00044	0.00413	CcSEcCtD
Ketamine—Decreased appetite—Vinorelbine—lung cancer	0.000424	0.00398	CcSEcCtD
Ketamine—Vision blurred—Cisplatin—lung cancer	0.000422	0.00396	CcSEcCtD
Ketamine—Pain—Vinorelbine—lung cancer	0.000417	0.00391	CcSEcCtD
Ketamine—Arrhythmia—Paclitaxel—lung cancer	0.000413	0.00387	CcSEcCtD
Ketamine—Anaphylactic shock—Irinotecan—lung cancer	0.000402	0.00377	CcSEcCtD
Ketamine—Erythema—Paclitaxel—lung cancer	0.000402	0.00377	CcSEcCtD
Ketamine—Shock—Irinotecan—lung cancer	0.000396	0.00371	CcSEcCtD
Ketamine—Anaphylactic shock—Gemcitabine—lung cancer	0.000392	0.00368	CcSEcCtD
Ketamine—Convulsion—Cisplatin—lung cancer	0.000388	0.00364	CcSEcCtD
Ketamine—Anorexia—Irinotecan—lung cancer	0.000384	0.0036	CcSEcCtD
Ketamine—Vision blurred—Paclitaxel—lung cancer	0.000379	0.00355	CcSEcCtD
Ketamine—Hypotension—Irinotecan—lung cancer	0.000376	0.00353	CcSEcCtD
Ketamine—Anorexia—Gemcitabine—lung cancer	0.000374	0.0035	CcSEcCtD
Ketamine—Vomiting—Vinblastine—lung cancer	0.000373	0.0035	CcSEcCtD
Ketamine—Hypotension—Gemcitabine—lung cancer	0.000366	0.00344	CcSEcCtD
Ketamine—Anaphylactic shock—Cisplatin—lung cancer	0.000365	0.00343	CcSEcCtD
Ketamine—Vomiting—Topotecan—lung cancer	0.000363	0.0034	CcSEcCtD
Ketamine—Rash—Topotecan—lung cancer	0.00036	0.00337	CcSEcCtD
Ketamine—Dermatitis—Topotecan—lung cancer	0.000359	0.00337	CcSEcCtD
Ketamine—Vomiting—Erlotinib—lung cancer	0.000359	0.00337	CcSEcCtD
Ketamine—Rash—Erlotinib—lung cancer	0.000356	0.00334	CcSEcCtD
Ketamine—Dermatitis—Erlotinib—lung cancer	0.000356	0.00333	CcSEcCtD
Ketamine—Convulsion—Etoposide—lung cancer	0.000355	0.00333	CcSEcCtD
Ketamine—Diplopia—Doxorubicin—lung cancer	0.000353	0.00331	CcSEcCtD
Ketamine—Decreased appetite—Irinotecan—lung cancer	0.00035	0.00328	CcSEcCtD
Ketamine—Arrhythmia—Docetaxel—lung cancer	0.00035	0.00328	CcSEcCtD
Ketamine—Nausea—Vinblastine—lung cancer	0.000349	0.00327	CcSEcCtD
Ketamine—Convulsion—Paclitaxel—lung cancer	0.000348	0.00327	CcSEcCtD
Ketamine—Anorexia—Cisplatin—lung cancer	0.000348	0.00327	CcSEcCtD
Ketamine—Pain—Irinotecan—lung cancer	0.000344	0.00323	CcSEcCtD
Ketamine—Hypotension—Cisplatin—lung cancer	0.000341	0.0032	CcSEcCtD
Ketamine—Erythema—Docetaxel—lung cancer	0.000341	0.0032	CcSEcCtD
Ketamine—Decreased appetite—Gemcitabine—lung cancer	0.000341	0.0032	CcSEcCtD
Ketamine—Nausea—Topotecan—lung cancer	0.000339	0.00318	CcSEcCtD
Ketamine—Pain—Gemcitabine—lung cancer	0.000335	0.00314	CcSEcCtD
Ketamine—Nausea—Erlotinib—lung cancer	0.000335	0.00314	CcSEcCtD
Ketamine—Anaphylactic shock—Etoposide—lung cancer	0.000335	0.00314	CcSEcCtD
Ketamine—Anaphylactic shock—Paclitaxel—lung cancer	0.000328	0.00308	CcSEcCtD
Ketamine—Shock—Paclitaxel—lung cancer	0.000323	0.00303	CcSEcCtD
Ketamine—Anorexia—Etoposide—lung cancer	0.000319	0.00299	CcSEcCtD
Ketamine—Decreased appetite—Cisplatin—lung cancer	0.000318	0.00298	CcSEcCtD
Ketamine—Anorexia—Paclitaxel—lung cancer	0.000313	0.00293	CcSEcCtD
Ketamine—Hypotension—Etoposide—lung cancer	0.000313	0.00293	CcSEcCtD
Ketamine—Pain—Cisplatin—lung cancer	0.000312	0.00293	CcSEcCtD
Ketamine—Vomiting—Vinorelbine—lung cancer	0.00031	0.00291	CcSEcCtD
Ketamine—Rash—Vinorelbine—lung cancer	0.000308	0.00289	CcSEcCtD
Ketamine—Dermatitis—Vinorelbine—lung cancer	0.000307	0.00288	CcSEcCtD
Ketamine—Hypotension—Paclitaxel—lung cancer	0.000307	0.00288	CcSEcCtD
Ketamine—Convulsion—Docetaxel—lung cancer	0.000295	0.00277	CcSEcCtD
Ketamine—Decreased appetite—Etoposide—lung cancer	0.000291	0.00273	CcSEcCtD
Ketamine—Nausea—Vinorelbine—lung cancer	0.00029	0.00272	CcSEcCtD
Ketamine—Pain—Etoposide—lung cancer	0.000286	0.00269	CcSEcCtD
Ketamine—Decreased appetite—Paclitaxel—lung cancer	0.000285	0.00268	CcSEcCtD
Ketamine—Pain—Paclitaxel—lung cancer	0.000281	0.00263	CcSEcCtD
Ketamine—Anaphylactic shock—Docetaxel—lung cancer	0.000278	0.00261	CcSEcCtD
Ketamine—Shock—Docetaxel—lung cancer	0.000274	0.00257	CcSEcCtD
Ketamine—Anorexia—Docetaxel—lung cancer	0.000265	0.00249	CcSEcCtD
Ketamine—Hypotension—Docetaxel—lung cancer	0.00026	0.00244	CcSEcCtD
Ketamine—Vomiting—Irinotecan—lung cancer	0.000256	0.0024	CcSEcCtD
Ketamine—Rash—Irinotecan—lung cancer	0.000254	0.00238	CcSEcCtD
Ketamine—Dermatitis—Irinotecan—lung cancer	0.000254	0.00238	CcSEcCtD
Ketamine—Vomiting—Gemcitabine—lung cancer	0.000249	0.00234	CcSEcCtD
Ketamine—Bradycardia—Doxorubicin—lung cancer	0.000249	0.00233	CcSEcCtD
Ketamine—Rash—Gemcitabine—lung cancer	0.000247	0.00232	CcSEcCtD
Ketamine—Dermatitis—Gemcitabine—lung cancer	0.000247	0.00232	CcSEcCtD
Ketamine—Erythema—Methotrexate—lung cancer	0.000246	0.0023	CcSEcCtD
Ketamine—Decreased appetite—Docetaxel—lung cancer	0.000242	0.00227	CcSEcCtD
Ketamine—Nausea—Irinotecan—lung cancer	0.000239	0.00224	CcSEcCtD
Ketamine—Pain—Docetaxel—lung cancer	0.000238	0.00223	CcSEcCtD
Ketamine—Nausea—Gemcitabine—lung cancer	0.000233	0.00218	CcSEcCtD
Ketamine—Vomiting—Cisplatin—lung cancer	0.000232	0.00218	CcSEcCtD
Ketamine—Vision blurred—Methotrexate—lung cancer	0.000232	0.00217	CcSEcCtD
Ketamine—Rash—Cisplatin—lung cancer	0.00023	0.00216	CcSEcCtD
Ketamine—Dermatitis—Cisplatin—lung cancer	0.00023	0.00216	CcSEcCtD
Ketamine—Arrhythmia—Doxorubicin—lung cancer	0.000218	0.00205	CcSEcCtD
Ketamine—Nausea—Cisplatin—lung cancer	0.000217	0.00204	CcSEcCtD
Ketamine—Convulsion—Methotrexate—lung cancer	0.000213	0.002	CcSEcCtD
Ketamine—Vomiting—Etoposide—lung cancer	0.000213	0.002	CcSEcCtD
Ketamine—Erythema—Doxorubicin—lung cancer	0.000213	0.002	CcSEcCtD
Ketamine—Rash—Etoposide—lung cancer	0.000211	0.00198	CcSEcCtD
Ketamine—Dermatitis—Etoposide—lung cancer	0.000211	0.00198	CcSEcCtD
Ketamine—Vomiting—Paclitaxel—lung cancer	0.000209	0.00196	CcSEcCtD
Ketamine—Rash—Paclitaxel—lung cancer	0.000207	0.00194	CcSEcCtD
Ketamine—Dermatitis—Paclitaxel—lung cancer	0.000207	0.00194	CcSEcCtD
Ketamine—Anaphylactic shock—Methotrexate—lung cancer	0.000201	0.00188	CcSEcCtD
Ketamine—Vision blurred—Doxorubicin—lung cancer	0.0002	0.00188	CcSEcCtD
Ketamine—Nausea—Etoposide—lung cancer	0.000199	0.00187	CcSEcCtD
Ketamine—Nausea—Paclitaxel—lung cancer	0.000195	0.00183	CcSEcCtD
Ketamine—Anorexia—Methotrexate—lung cancer	0.000191	0.00179	CcSEcCtD
Ketamine—Hypotension—Methotrexate—lung cancer	0.000187	0.00176	CcSEcCtD
Ketamine—Convulsion—Doxorubicin—lung cancer	0.000184	0.00173	CcSEcCtD
Ketamine—Vomiting—Docetaxel—lung cancer	0.000177	0.00166	CcSEcCtD
Ketamine—Rash—Docetaxel—lung cancer	0.000175	0.00165	CcSEcCtD
Ketamine—Dermatitis—Docetaxel—lung cancer	0.000175	0.00164	CcSEcCtD
Ketamine—Decreased appetite—Methotrexate—lung cancer	0.000174	0.00163	CcSEcCtD
Ketamine—Anaphylactic shock—Doxorubicin—lung cancer	0.000174	0.00163	CcSEcCtD
Ketamine—Pain—Methotrexate—lung cancer	0.000171	0.00161	CcSEcCtD
Ketamine—Shock—Doxorubicin—lung cancer	0.000171	0.0016	CcSEcCtD
Ketamine—Anorexia—Doxorubicin—lung cancer	0.000166	0.00155	CcSEcCtD
Ketamine—Nausea—Docetaxel—lung cancer	0.000165	0.00155	CcSEcCtD
Ketamine—Hypotension—Doxorubicin—lung cancer	0.000162	0.00152	CcSEcCtD
Ketamine—Decreased appetite—Doxorubicin—lung cancer	0.000151	0.00142	CcSEcCtD
Ketamine—Pain—Doxorubicin—lung cancer	0.000148	0.00139	CcSEcCtD
Ketamine—Vomiting—Methotrexate—lung cancer	0.000127	0.0012	CcSEcCtD
Ketamine—Rash—Methotrexate—lung cancer	0.000126	0.00119	CcSEcCtD
Ketamine—Dermatitis—Methotrexate—lung cancer	0.000126	0.00118	CcSEcCtD
Ketamine—Nausea—Methotrexate—lung cancer	0.000119	0.00112	CcSEcCtD
Ketamine—Vomiting—Doxorubicin—lung cancer	0.00011	0.00104	CcSEcCtD
Ketamine—Rash—Doxorubicin—lung cancer	0.000109	0.00103	CcSEcCtD
Ketamine—Dermatitis—Doxorubicin—lung cancer	0.000109	0.00103	CcSEcCtD
Ketamine—Nausea—Doxorubicin—lung cancer	0.000103	0.000967	CcSEcCtD
Ketamine—DRD2—Signaling by GPCR—IL2—lung cancer	6.38e-06	3.46e-05	CbGpPWpGaD
Ketamine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—lung cancer	6.37e-06	3.45e-05	CbGpPWpGaD
Ketamine—DRD2—Signaling Pathways—TERT—lung cancer	6.35e-06	3.44e-05	CbGpPWpGaD
Ketamine—OPRD1—Signaling Pathways—MMP9—lung cancer	6.35e-06	3.44e-05	CbGpPWpGaD
Ketamine—OPRD1—Signaling Pathways—CDKN1A—lung cancer	6.32e-06	3.43e-05	CbGpPWpGaD
Ketamine—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—lung cancer	6.31e-06	3.42e-05	CbGpPWpGaD
Ketamine—OPRD1—Signaling Pathways—PTEN—lung cancer	6.31e-06	3.42e-05	CbGpPWpGaD
Ketamine—CYP2C8—Metabolism—ABCB1—lung cancer	6.31e-06	3.42e-05	CbGpPWpGaD
Ketamine—ABCB1—Metabolism—STK11—lung cancer	6.28e-06	3.4e-05	CbGpPWpGaD
Ketamine—CYP3A4—Metabolism—UGT1A1—lung cancer	6.26e-06	3.39e-05	CbGpPWpGaD
Ketamine—OPRM1—Signaling Pathways—MAP2K1—lung cancer	6.25e-06	3.39e-05	CbGpPWpGaD
Ketamine—OPRM1—Signaling Pathways—PIK3CD—lung cancer	6.21e-06	3.37e-05	CbGpPWpGaD
Ketamine—CYP2C8—Metabolism—TYMS—lung cancer	6.2e-06	3.36e-05	CbGpPWpGaD
Ketamine—PTGS1—Metabolism—PIK3CD—lung cancer	6.19e-06	3.36e-05	CbGpPWpGaD
Ketamine—DRD2—Signaling Pathways—FGFR1—lung cancer	6.17e-06	3.34e-05	CbGpPWpGaD
Ketamine—OPRD1—Signaling by GPCR—AKT1—lung cancer	6.16e-06	3.34e-05	CbGpPWpGaD
Ketamine—OPRK1—Signaling Pathways—CXCL8—lung cancer	6.15e-06	3.34e-05	CbGpPWpGaD
Ketamine—OPRM1—GPCR downstream signaling—PIK3CA—lung cancer	6.15e-06	3.33e-05	CbGpPWpGaD
Ketamine—CYP2C8—Metabolism—GSTM1—lung cancer	6.13e-06	3.32e-05	CbGpPWpGaD
Ketamine—OPRK1—Signaling by GPCR—HRAS—lung cancer	6.11e-06	3.31e-05	CbGpPWpGaD
Ketamine—PTGS1—Metabolism—ALB—lung cancer	6.11e-06	3.31e-05	CbGpPWpGaD
Ketamine—OPRM1—Signaling by GPCR—KRAS—lung cancer	6.08e-06	3.3e-05	CbGpPWpGaD
Ketamine—DRD2—Signaling Pathways—HIF1A—lung cancer	6.08e-06	3.29e-05	CbGpPWpGaD
Ketamine—CYP3A4—Metabolism—GNG11—lung cancer	6.04e-06	3.27e-05	CbGpPWpGaD
Ketamine—OPRD1—Signaling Pathways—EP300—lung cancer	6.02e-06	3.26e-05	CbGpPWpGaD
Ketamine—OPRK1—GPCR downstream signaling—AKT1—lung cancer	5.94e-06	3.22e-05	CbGpPWpGaD
Ketamine—OPRK1—Signaling Pathways—CASP3—lung cancer	5.89e-06	3.19e-05	CbGpPWpGaD
Ketamine—CYP2B6—Metabolism—APOA1—lung cancer	5.88e-06	3.19e-05	CbGpPWpGaD
Ketamine—OPRK1—Signaling Pathways—IL2—lung cancer	5.88e-06	3.19e-05	CbGpPWpGaD
Ketamine—CYP2C9—Metabolism—STK11—lung cancer	5.86e-06	3.18e-05	CbGpPWpGaD
Ketamine—DRD2—Signaling Pathways—APOA1—lung cancer	5.86e-06	3.18e-05	CbGpPWpGaD
Ketamine—OPRD1—Signaling Pathways—SRC—lung cancer	5.85e-06	3.17e-05	CbGpPWpGaD
Ketamine—OPRK1—Signaling by GPCR—IL6—lung cancer	5.85e-06	3.17e-05	CbGpPWpGaD
Ketamine—DRD2—Signaling Pathways—KDR—lung cancer	5.81e-06	3.15e-05	CbGpPWpGaD
Ketamine—ABCB1—Metabolism—GSTP1—lung cancer	5.81e-06	3.15e-05	CbGpPWpGaD
Ketamine—CYP2C8—Metabolism—CYP1A1—lung cancer	5.81e-06	3.15e-05	CbGpPWpGaD
Ketamine—CYP2C8—Metabolism—ERCC2—lung cancer	5.76e-06	3.12e-05	CbGpPWpGaD
Ketamine—CYP3A4—Metabolism—ALDOA—lung cancer	5.75e-06	3.12e-05	CbGpPWpGaD
Ketamine—OPRK1—Signaling Pathways—CCND1—lung cancer	5.73e-06	3.11e-05	CbGpPWpGaD
Ketamine—OPRK1—Signaling Pathways—JUN—lung cancer	5.72e-06	3.1e-05	CbGpPWpGaD
Ketamine—OPRD1—Signaling Pathways—VEGFA—lung cancer	5.7e-06	3.09e-05	CbGpPWpGaD
Ketamine—ABCB1—Metabolism—CAT—lung cancer	5.65e-06	3.06e-05	CbGpPWpGaD
Ketamine—OPRD1—Signaling Pathways—STAT3—lung cancer	5.64e-06	3.06e-05	CbGpPWpGaD
Ketamine—OPRD1—Signaling Pathways—NRAS—lung cancer	5.63e-06	3.05e-05	CbGpPWpGaD
Ketamine—OPRM1—Signaling by GPCR—PIK3CA—lung cancer	5.58e-06	3.03e-05	CbGpPWpGaD
Ketamine—CYP3A4—Metabolism—NCOA3—lung cancer	5.58e-06	3.02e-05	CbGpPWpGaD
Ketamine—OPRK1—Signaling Pathways—MMP9—lung cancer	5.57e-06	3.02e-05	CbGpPWpGaD
Ketamine—OPRM1—Signaling Pathways—MDM2—lung cancer	5.56e-06	3.02e-05	CbGpPWpGaD
Ketamine—OPRK1—Signaling Pathways—CDKN1A—lung cancer	5.55e-06	3.01e-05	CbGpPWpGaD
Ketamine—OPRM1—Signaling Pathways—RAF1—lung cancer	5.54e-06	3.01e-05	CbGpPWpGaD
Ketamine—OPRK1—Signaling Pathways—PTEN—lung cancer	5.53e-06	3e-05	CbGpPWpGaD
Ketamine—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—lung cancer	5.5e-06	2.98e-05	CbGpPWpGaD
Ketamine—OPRM1—Signaling Pathways—ERBB2—lung cancer	5.48e-06	2.97e-05	CbGpPWpGaD
Ketamine—CYP3A4—Metabolism—ADCY1—lung cancer	5.43e-06	2.94e-05	CbGpPWpGaD
Ketamine—CYP3A4—Metabolism—ABCG2—lung cancer	5.43e-06	2.94e-05	CbGpPWpGaD
Ketamine—CYP2C9—Metabolism—GSTP1—lung cancer	5.43e-06	2.94e-05	CbGpPWpGaD
Ketamine—OPRM1—Signaling Pathways—MTOR—lung cancer	5.41e-06	2.93e-05	CbGpPWpGaD
Ketamine—OPRM1—Signaling Pathways—PIK3CB—lung cancer	5.41e-06	2.93e-05	CbGpPWpGaD
Ketamine—ABCB1—Metabolism—TYMS—lung cancer	5.4e-06	2.93e-05	CbGpPWpGaD
Ketamine—OPRK1—Signaling by GPCR—AKT1—lung cancer	5.4e-06	2.93e-05	CbGpPWpGaD
Ketamine—PTGS1—Metabolism—PIK3CB—lung cancer	5.4e-06	2.93e-05	CbGpPWpGaD
Ketamine—OPRD1—Signaling Pathways—MAPK3—lung cancer	5.39e-06	2.92e-05	CbGpPWpGaD
Ketamine—CYP2B6—Metabolism—PIK3CG—lung cancer	5.37e-06	2.91e-05	CbGpPWpGaD
Ketamine—DRD2—Signaling Pathways—PIK3CG—lung cancer	5.35e-06	2.9e-05	CbGpPWpGaD
Ketamine—DRD2—Signaling Pathways—APC—lung cancer	5.35e-06	2.9e-05	CbGpPWpGaD
Ketamine—DRD2—Signaling Pathways—KIT—lung cancer	5.35e-06	2.9e-05	CbGpPWpGaD
Ketamine—DRD2—Signaling by GPCR—NRAS—lung cancer	5.35e-06	2.9e-05	CbGpPWpGaD
Ketamine—PTGS1—Metabolism—PTGS2—lung cancer	5.35e-06	2.9e-05	CbGpPWpGaD
Ketamine—ABCB1—Metabolism—GSTM1—lung cancer	5.34e-06	2.89e-05	CbGpPWpGaD
Ketamine—CYP3A4—Metabolism—HPGDS—lung cancer	5.32e-06	2.89e-05	CbGpPWpGaD
Ketamine—CYP3A4—Metabolism—ENO2—lung cancer	5.32e-06	2.89e-05	CbGpPWpGaD
Ketamine—DRD2—Signaling Pathways—EGF—lung cancer	5.29e-06	2.87e-05	CbGpPWpGaD
Ketamine—CYP3A4—Metabolism—PPP2R1B—lung cancer	5.29e-06	2.87e-05	CbGpPWpGaD
Ketamine—CYP2C9—Metabolism—CAT—lung cancer	5.28e-06	2.86e-05	CbGpPWpGaD
Ketamine—OPRK1—Signaling Pathways—EP300—lung cancer	5.28e-06	2.86e-05	CbGpPWpGaD
Ketamine—CYP2C9—Metabolism of lipids and lipoproteins—EP300—lung cancer	5.25e-06	2.85e-05	CbGpPWpGaD
Ketamine—OPRD1—Signaling Pathways—MYC—lung cancer	5.24e-06	2.84e-05	CbGpPWpGaD
Ketamine—OPRM1—Signaling Pathways—CXCL8—lung cancer	5.2e-06	2.82e-05	CbGpPWpGaD
Ketamine—OPRM1—Signaling by GPCR—HRAS—lung cancer	5.17e-06	2.8e-05	CbGpPWpGaD
Ketamine—CYP3A4—Metabolism—GSTT1—lung cancer	5.16e-06	2.8e-05	CbGpPWpGaD
Ketamine—CYP2C9—Metabolism—ABCB1—lung cancer	5.14e-06	2.78e-05	CbGpPWpGaD
Ketamine—OPRK1—Signaling Pathways—SRC—lung cancer	5.13e-06	2.78e-05	CbGpPWpGaD
Ketamine—OPRD1—Signaling Pathways—EGFR—lung cancer	5.13e-06	2.78e-05	CbGpPWpGaD
Ketamine—DRD2—Signaling by GPCR—MAPK3—lung cancer	5.13e-06	2.78e-05	CbGpPWpGaD
Ketamine—CYP2B6—Metabolism—POMC—lung cancer	5.11e-06	2.77e-05	CbGpPWpGaD
Ketamine—CYP3A4—Metabolism—CYP2A6—lung cancer	5.1e-06	2.77e-05	CbGpPWpGaD
Ketamine—CYP3A4—Metabolism—GCLC—lung cancer	5.1e-06	2.77e-05	CbGpPWpGaD
Ketamine—DRD2—Signaling Pathways—POMC—lung cancer	5.1e-06	2.76e-05	CbGpPWpGaD
Ketamine—ABCB1—Metabolism—CYP1A1—lung cancer	5.06e-06	2.74e-05	CbGpPWpGaD
Ketamine—CYP2C9—Metabolism—TYMS—lung cancer	5.04e-06	2.73e-05	CbGpPWpGaD
Ketamine—DRD2—Signaling Pathways—BRAF—lung cancer	5.03e-06	2.73e-05	CbGpPWpGaD
Ketamine—OPRM1—GPCR downstream signaling—AKT1—lung cancer	5.02e-06	2.72e-05	CbGpPWpGaD
Ketamine—ABCB1—Metabolism—ERCC2—lung cancer	5.02e-06	2.72e-05	CbGpPWpGaD
Ketamine—OPRK1—Signaling Pathways—VEGFA—lung cancer	5e-06	2.71e-05	CbGpPWpGaD
Ketamine—CYP2C9—Metabolism—GSTM1—lung cancer	4.99e-06	2.7e-05	CbGpPWpGaD
Ketamine—CYP2C8—Metabolism—APOA1—lung cancer	4.98e-06	2.7e-05	CbGpPWpGaD
Ketamine—CYP2B6—Metabolism—CREBBP—lung cancer	4.98e-06	2.7e-05	CbGpPWpGaD
Ketamine—OPRM1—Signaling Pathways—CASP3—lung cancer	4.98e-06	2.7e-05	CbGpPWpGaD
Ketamine—OPRM1—Signaling Pathways—IL2—lung cancer	4.97e-06	2.69e-05	CbGpPWpGaD
Ketamine—DRD2—Signaling Pathways—IL6R—lung cancer	4.97e-06	2.69e-05	CbGpPWpGaD
Ketamine—DRD2—Signaling Pathways—CREBBP—lung cancer	4.96e-06	2.69e-05	CbGpPWpGaD
Ketamine—OPRK1—Signaling Pathways—STAT3—lung cancer	4.95e-06	2.68e-05	CbGpPWpGaD
Ketamine—OPRM1—Signaling by GPCR—IL6—lung cancer	4.95e-06	2.68e-05	CbGpPWpGaD
Ketamine—OPRK1—Signaling Pathways—NRAS—lung cancer	4.94e-06	2.68e-05	CbGpPWpGaD
Ketamine—DRD2—Signaling by GPCR—EGFR—lung cancer	4.88e-06	2.64e-05	CbGpPWpGaD
Ketamine—OPRD1—Signaling Pathways—KRAS—lung cancer	4.85e-06	2.63e-05	CbGpPWpGaD
Ketamine—OPRM1—Signaling Pathways—CCND1—lung cancer	4.85e-06	2.63e-05	CbGpPWpGaD
Ketamine—CYP3A4—Metabolism—ENO1—lung cancer	4.84e-06	2.62e-05	CbGpPWpGaD
Ketamine—OPRM1—Signaling Pathways—JUN—lung cancer	4.84e-06	2.62e-05	CbGpPWpGaD
Ketamine—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—lung cancer	4.77e-06	2.59e-05	CbGpPWpGaD
Ketamine—DRD2—Signaling Pathways—MAP2K1—lung cancer	4.74e-06	2.57e-05	CbGpPWpGaD
Ketamine—OPRK1—Signaling Pathways—MAPK3—lung cancer	4.73e-06	2.56e-05	CbGpPWpGaD
Ketamine—CYP2C9—Metabolism—CYP1A1—lung cancer	4.73e-06	2.56e-05	CbGpPWpGaD
Ketamine—CYP2B6—Metabolism—PIK3CD—lung cancer	4.72e-06	2.56e-05	CbGpPWpGaD
Ketamine—DRD2—Signaling Pathways—PIK3CD—lung cancer	4.71e-06	2.55e-05	CbGpPWpGaD
Ketamine—OPRM1—Signaling Pathways—MMP9—lung cancer	4.7e-06	2.55e-05	CbGpPWpGaD
Ketamine—CYP2C9—Metabolism—ERCC2—lung cancer	4.69e-06	2.54e-05	CbGpPWpGaD
Ketamine—OPRM1—Signaling Pathways—CDKN1A—lung cancer	4.69e-06	2.54e-05	CbGpPWpGaD
Ketamine—OPRM1—Signaling Pathways—PTEN—lung cancer	4.68e-06	2.54e-05	CbGpPWpGaD
Ketamine—PTGS1—Metabolism—PTEN—lung cancer	4.66e-06	2.53e-05	CbGpPWpGaD
Ketamine—CYP2B6—Metabolism—ALB—lung cancer	4.66e-06	2.53e-05	CbGpPWpGaD
Ketamine—DRD2—GPCR downstream signaling—PIK3CA—lung cancer	4.66e-06	2.53e-05	CbGpPWpGaD
Ketamine—DRD2—Signaling by GPCR—KRAS—lung cancer	4.61e-06	2.5e-05	CbGpPWpGaD
Ketamine—OPRK1—Signaling Pathways—MYC—lung cancer	4.6e-06	2.49e-05	CbGpPWpGaD
Ketamine—OPRM1—Signaling by GPCR—AKT1—lung cancer	4.56e-06	2.47e-05	CbGpPWpGaD
Ketamine—CYP2C8—Metabolism—PIK3CG—lung cancer	4.55e-06	2.47e-05	CbGpPWpGaD
Ketamine—OPRK1—Signaling Pathways—EGFR—lung cancer	4.5e-06	2.44e-05	CbGpPWpGaD
Ketamine—OPRM1—Signaling Pathways—EP300—lung cancer	4.46e-06	2.42e-05	CbGpPWpGaD
Ketamine—OPRD1—Signaling Pathways—PIK3CA—lung cancer	4.45e-06	2.41e-05	CbGpPWpGaD
Ketamine—PTGS1—Metabolism—EP300—lung cancer	4.45e-06	2.41e-05	CbGpPWpGaD
Ketamine—ABCB1—Metabolism—APOA1—lung cancer	4.34e-06	2.35e-05	CbGpPWpGaD
Ketamine—CYP3A4—Metabolism—CYP2E1—lung cancer	4.34e-06	2.35e-05	CbGpPWpGaD
Ketamine—OPRM1—Signaling Pathways—SRC—lung cancer	4.34e-06	2.35e-05	CbGpPWpGaD
Ketamine—CYP2C8—Metabolism—POMC—lung cancer	4.33e-06	2.35e-05	CbGpPWpGaD
Ketamine—OPRD1—Signaling Pathways—TP53—lung cancer	4.31e-06	2.33e-05	CbGpPWpGaD
Ketamine—CYP3A4—Metabolism—NQO1—lung cancer	4.29e-06	2.33e-05	CbGpPWpGaD
Ketamine—OPRK1—Signaling Pathways—KRAS—lung cancer	4.25e-06	2.3e-05	CbGpPWpGaD
Ketamine—DRD2—Signaling by GPCR—PIK3CA—lung cancer	4.23e-06	2.29e-05	CbGpPWpGaD
Ketamine—OPRM1—Signaling Pathways—VEGFA—lung cancer	4.22e-06	2.29e-05	CbGpPWpGaD
Ketamine—CYP2C8—Metabolism—CREBBP—lung cancer	4.22e-06	2.29e-05	CbGpPWpGaD
Ketamine—DRD2—Signaling Pathways—MDM2—lung cancer	4.22e-06	2.29e-05	CbGpPWpGaD
Ketamine—DRD2—Signaling Pathways—RAF1—lung cancer	4.2e-06	2.28e-05	CbGpPWpGaD
Ketamine—OPRM1—Signaling Pathways—STAT3—lung cancer	4.18e-06	2.27e-05	CbGpPWpGaD
Ketamine—OPRM1—Signaling Pathways—NRAS—lung cancer	4.17e-06	2.26e-05	CbGpPWpGaD
Ketamine—DRD2—Signaling Pathways—ERBB2—lung cancer	4.16e-06	2.25e-05	CbGpPWpGaD
Ketamine—OPRD1—Signaling Pathways—HRAS—lung cancer	4.12e-06	2.23e-05	CbGpPWpGaD
Ketamine—CYP2B6—Metabolism—PIK3CB—lung cancer	4.12e-06	2.23e-05	CbGpPWpGaD
Ketamine—DRD2—Signaling Pathways—MTOR—lung cancer	4.1e-06	2.22e-05	CbGpPWpGaD
Ketamine—DRD2—Signaling Pathways—PIK3CB—lung cancer	4.1e-06	2.22e-05	CbGpPWpGaD
Ketamine—CYP2B6—Metabolism—PTGS2—lung cancer	4.08e-06	2.21e-05	CbGpPWpGaD
Ketamine—CYP2C9—Metabolism—APOA1—lung cancer	4.05e-06	2.2e-05	CbGpPWpGaD
Ketamine—CYP2C8—Metabolism—PIK3CD—lung cancer	4e-06	2.17e-05	CbGpPWpGaD
Ketamine—OPRM1—Signaling Pathways—MAPK3—lung cancer	4e-06	2.17e-05	CbGpPWpGaD
Ketamine—ABCB1—Metabolism—PIK3CG—lung cancer	3.96e-06	2.15e-05	CbGpPWpGaD
Ketamine—CYP2C8—Metabolism—ALB—lung cancer	3.95e-06	2.14e-05	CbGpPWpGaD
Ketamine—OPRD1—Signaling Pathways—IL6—lung cancer	3.94e-06	2.14e-05	CbGpPWpGaD
Ketamine—DRD2—Signaling Pathways—CXCL8—lung cancer	3.94e-06	2.14e-05	CbGpPWpGaD
Ketamine—DRD2—Signaling by GPCR—HRAS—lung cancer	3.92e-06	2.12e-05	CbGpPWpGaD
Ketamine—OPRK1—Signaling Pathways—PIK3CA—lung cancer	3.9e-06	2.12e-05	CbGpPWpGaD
Ketamine—OPRM1—Signaling Pathways—MYC—lung cancer	3.89e-06	2.11e-05	CbGpPWpGaD
Ketamine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—lung cancer	3.88e-06	2.11e-05	CbGpPWpGaD
Ketamine—CYP3A4—Metabolism—STK11—lung cancer	3.87e-06	2.1e-05	CbGpPWpGaD
Ketamine—DRD2—GPCR downstream signaling—AKT1—lung cancer	3.81e-06	2.06e-05	CbGpPWpGaD
Ketamine—OPRM1—Signaling Pathways—EGFR—lung cancer	3.8e-06	2.06e-05	CbGpPWpGaD
Ketamine—OPRK1—Signaling Pathways—TP53—lung cancer	3.78e-06	2.05e-05	CbGpPWpGaD
Ketamine—DRD2—Signaling Pathways—CASP3—lung cancer	3.77e-06	2.05e-05	CbGpPWpGaD
Ketamine—ABCB1—Metabolism—POMC—lung cancer	3.77e-06	2.04e-05	CbGpPWpGaD
Ketamine—DRD2—Signaling Pathways—IL2—lung cancer	3.77e-06	2.04e-05	CbGpPWpGaD
Ketamine—DRD2—Signaling by GPCR—IL6—lung cancer	3.75e-06	2.03e-05	CbGpPWpGaD
Ketamine—CYP2C9—Metabolism—PIK3CG—lung cancer	3.7e-06	2.01e-05	CbGpPWpGaD
Ketamine—ABCB1—Metabolism—CREBBP—lung cancer	3.67e-06	1.99e-05	CbGpPWpGaD
Ketamine—DRD2—Signaling Pathways—CCND1—lung cancer	3.67e-06	1.99e-05	CbGpPWpGaD
Ketamine—DRD2—Signaling Pathways—JUN—lung cancer	3.66e-06	1.99e-05	CbGpPWpGaD
Ketamine—OPRD1—Signaling Pathways—AKT1—lung cancer	3.64e-06	1.97e-05	CbGpPWpGaD
Ketamine—OPRK1—Signaling Pathways—HRAS—lung cancer	3.61e-06	1.96e-05	CbGpPWpGaD
Ketamine—OPRM1—Signaling Pathways—KRAS—lung cancer	3.59e-06	1.95e-05	CbGpPWpGaD
Ketamine—CYP3A4—Metabolism—GSTP1—lung cancer	3.58e-06	1.94e-05	CbGpPWpGaD
Ketamine—DRD2—Signaling Pathways—MMP9—lung cancer	3.57e-06	1.93e-05	CbGpPWpGaD
Ketamine—CYP2B6—Metabolism—PTEN—lung cancer	3.56e-06	1.93e-05	CbGpPWpGaD
Ketamine—DRD2—Signaling Pathways—CDKN1A—lung cancer	3.55e-06	1.93e-05	CbGpPWpGaD
Ketamine—DRD2—Signaling Pathways—PTEN—lung cancer	3.54e-06	1.92e-05	CbGpPWpGaD
Ketamine—CYP2C9—Metabolism—POMC—lung cancer	3.52e-06	1.91e-05	CbGpPWpGaD
Ketamine—CYP2C8—Metabolism—PIK3CB—lung cancer	3.49e-06	1.89e-05	CbGpPWpGaD
Ketamine—ABCB1—Metabolism—PIK3CD—lung cancer	3.48e-06	1.89e-05	CbGpPWpGaD
Ketamine—CYP3A4—Metabolism—CAT—lung cancer	3.48e-06	1.89e-05	CbGpPWpGaD
Ketamine—DRD2—Signaling by GPCR—AKT1—lung cancer	3.46e-06	1.87e-05	CbGpPWpGaD
Ketamine—OPRK1—Signaling Pathways—IL6—lung cancer	3.46e-06	1.87e-05	CbGpPWpGaD
Ketamine—CYP2C8—Metabolism—PTGS2—lung cancer	3.45e-06	1.87e-05	CbGpPWpGaD
Ketamine—ABCB1—Metabolism—ALB—lung cancer	3.44e-06	1.86e-05	CbGpPWpGaD
Ketamine—CYP2C9—Metabolism—CREBBP—lung cancer	3.43e-06	1.86e-05	CbGpPWpGaD
Ketamine—CYP2B6—Metabolism—EP300—lung cancer	3.39e-06	1.84e-05	CbGpPWpGaD
Ketamine—CYP3A4—Metabolism—ABCB1—lung cancer	3.39e-06	1.84e-05	CbGpPWpGaD
Ketamine—DRD2—Signaling Pathways—EP300—lung cancer	3.38e-06	1.83e-05	CbGpPWpGaD
Ketamine—CYP3A4—Metabolism—TYMS—lung cancer	3.33e-06	1.8e-05	CbGpPWpGaD
Ketamine—OPRM1—Signaling Pathways—PIK3CA—lung cancer	3.3e-06	1.79e-05	CbGpPWpGaD
Ketamine—PTGS1—Metabolism—PIK3CA—lung cancer	3.29e-06	1.78e-05	CbGpPWpGaD
Ketamine—CYP3A4—Metabolism—GSTM1—lung cancer	3.29e-06	1.78e-05	CbGpPWpGaD
Ketamine—DRD2—Signaling Pathways—SRC—lung cancer	3.29e-06	1.78e-05	CbGpPWpGaD
Ketamine—CYP2C9—Metabolism—PIK3CD—lung cancer	3.25e-06	1.76e-05	CbGpPWpGaD
Ketamine—CYP2C9—Metabolism—ALB—lung cancer	3.21e-06	1.74e-05	CbGpPWpGaD
Ketamine—DRD2—Signaling Pathways—VEGFA—lung cancer	3.2e-06	1.74e-05	CbGpPWpGaD
Ketamine—OPRM1—Signaling Pathways—TP53—lung cancer	3.19e-06	1.73e-05	CbGpPWpGaD
Ketamine—OPRK1—Signaling Pathways—AKT1—lung cancer	3.19e-06	1.73e-05	CbGpPWpGaD
Ketamine—DRD2—Signaling Pathways—STAT3—lung cancer	3.17e-06	1.72e-05	CbGpPWpGaD
Ketamine—DRD2—Signaling Pathways—NRAS—lung cancer	3.16e-06	1.71e-05	CbGpPWpGaD
Ketamine—CYP3A4—Metabolism—CYP1A1—lung cancer	3.12e-06	1.69e-05	CbGpPWpGaD
Ketamine—CYP3A4—Metabolism—ERCC2—lung cancer	3.09e-06	1.68e-05	CbGpPWpGaD
Ketamine—OPRM1—Signaling Pathways—HRAS—lung cancer	3.05e-06	1.65e-05	CbGpPWpGaD
Ketamine—ABCB1—Metabolism—PIK3CB—lung cancer	3.04e-06	1.65e-05	CbGpPWpGaD
Ketamine—DRD2—Signaling Pathways—MAPK3—lung cancer	3.03e-06	1.64e-05	CbGpPWpGaD
Ketamine—CYP2C8—Metabolism—PTEN—lung cancer	3.01e-06	1.63e-05	CbGpPWpGaD
Ketamine—ABCB1—Metabolism—PTGS2—lung cancer	3.01e-06	1.63e-05	CbGpPWpGaD
Ketamine—DRD2—Signaling Pathways—MYC—lung cancer	2.95e-06	1.6e-05	CbGpPWpGaD
Ketamine—OPRM1—Signaling Pathways—IL6—lung cancer	2.92e-06	1.58e-05	CbGpPWpGaD
Ketamine—DRD2—Signaling Pathways—EGFR—lung cancer	2.88e-06	1.56e-05	CbGpPWpGaD
Ketamine—CYP2C8—Metabolism—EP300—lung cancer	2.87e-06	1.56e-05	CbGpPWpGaD
Ketamine—CYP2C9—Metabolism—PIK3CB—lung cancer	2.84e-06	1.54e-05	CbGpPWpGaD
Ketamine—CYP2C9—Metabolism—PTGS2—lung cancer	2.81e-06	1.52e-05	CbGpPWpGaD
Ketamine—DRD2—Signaling Pathways—KRAS—lung cancer	2.72e-06	1.48e-05	CbGpPWpGaD
Ketamine—OPRM1—Signaling Pathways—AKT1—lung cancer	2.7e-06	1.46e-05	CbGpPWpGaD
Ketamine—PTGS1—Metabolism—AKT1—lung cancer	2.69e-06	1.46e-05	CbGpPWpGaD
Ketamine—CYP3A4—Metabolism—APOA1—lung cancer	2.67e-06	1.45e-05	CbGpPWpGaD
Ketamine—ABCB1—Metabolism—PTEN—lung cancer	2.62e-06	1.42e-05	CbGpPWpGaD
Ketamine—CYP2B6—Metabolism—PIK3CA—lung cancer	2.51e-06	1.36e-05	CbGpPWpGaD
Ketamine—ABCB1—Metabolism—EP300—lung cancer	2.5e-06	1.36e-05	CbGpPWpGaD
Ketamine—DRD2—Signaling Pathways—PIK3CA—lung cancer	2.5e-06	1.36e-05	CbGpPWpGaD
Ketamine—CYP2C9—Metabolism—PTEN—lung cancer	2.45e-06	1.33e-05	CbGpPWpGaD
Ketamine—CYP3A4—Metabolism—PIK3CG—lung cancer	2.44e-06	1.32e-05	CbGpPWpGaD
Ketamine—DRD2—Signaling Pathways—TP53—lung cancer	2.42e-06	1.31e-05	CbGpPWpGaD
Ketamine—CYP2C9—Metabolism—EP300—lung cancer	2.34e-06	1.27e-05	CbGpPWpGaD
Ketamine—CYP3A4—Metabolism—POMC—lung cancer	2.32e-06	1.26e-05	CbGpPWpGaD
Ketamine—DRD2—Signaling Pathways—HRAS—lung cancer	2.31e-06	1.25e-05	CbGpPWpGaD
Ketamine—CYP3A4—Metabolism—CREBBP—lung cancer	2.26e-06	1.23e-05	CbGpPWpGaD
Ketamine—DRD2—Signaling Pathways—IL6—lung cancer	2.21e-06	1.2e-05	CbGpPWpGaD
Ketamine—CYP3A4—Metabolism—PIK3CD—lung cancer	2.15e-06	1.16e-05	CbGpPWpGaD
Ketamine—CYP2C8—Metabolism—PIK3CA—lung cancer	2.12e-06	1.15e-05	CbGpPWpGaD
Ketamine—CYP3A4—Metabolism—ALB—lung cancer	2.12e-06	1.15e-05	CbGpPWpGaD
Ketamine—CYP2B6—Metabolism—AKT1—lung cancer	2.05e-06	1.11e-05	CbGpPWpGaD
Ketamine—DRD2—Signaling Pathways—AKT1—lung cancer	2.04e-06	1.11e-05	CbGpPWpGaD
Ketamine—CYP3A4—Metabolism—PIK3CB—lung cancer	1.87e-06	1.01e-05	CbGpPWpGaD
Ketamine—CYP3A4—Metabolism—PTGS2—lung cancer	1.85e-06	1e-05	CbGpPWpGaD
Ketamine—ABCB1—Metabolism—PIK3CA—lung cancer	1.85e-06	1e-05	CbGpPWpGaD
Ketamine—CYP2C8—Metabolism—AKT1—lung cancer	1.74e-06	9.41e-06	CbGpPWpGaD
Ketamine—CYP2C9—Metabolism—PIK3CA—lung cancer	1.73e-06	9.37e-06	CbGpPWpGaD
Ketamine—CYP3A4—Metabolism—PTEN—lung cancer	1.62e-06	8.76e-06	CbGpPWpGaD
Ketamine—CYP3A4—Metabolism—EP300—lung cancer	1.54e-06	8.36e-06	CbGpPWpGaD
Ketamine—ABCB1—Metabolism—AKT1—lung cancer	1.51e-06	8.2e-06	CbGpPWpGaD
Ketamine—CYP2C9—Metabolism—AKT1—lung cancer	1.41e-06	7.66e-06	CbGpPWpGaD
Ketamine—CYP3A4—Metabolism—PIK3CA—lung cancer	1.14e-06	6.18e-06	CbGpPWpGaD
Ketamine—CYP3A4—Metabolism—AKT1—lung cancer	9.32e-07	5.05e-06	CbGpPWpGaD
